Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma

EGFR-mutated lung adenocarcinoma patients treated with gefitinib and osimertinib show a therapeutic benefit limited by the appearance of secondary mutations, such as EGFR(T790M) and EGFR(C797S). It is generally assumed that these secondary mutations render EGFR completely unresponsive to the inhibit...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Invest
Glavni autori: Bousquet Mur, Emilie, Bernardo, Sara, Papon, Laura, Mancini, Maicol, Fabbrizio, Eric, Goussard, Marion, Ferrer, Irene, Giry, Anais, Quantin, Xavier, Pujol, Jean-Louis, Calvayrac, Olivier, Moll, Herwig P., Glasson, Yaël, Pirot, Nelly, Turtoi, Andrei, Cañamero, Marta, Wong, Kwok-Kin, Yarden, Yosef, Casanova, Emilio, Soria, Jean-Charles, Colinge, Jacques, Siebel, Christian W., Mazieres, Julien, Favre, Gilles, Paz-Ares, Luis, Maraver, Antonio
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2019
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6994195/
https://ncbi.nlm.nih.gov/pubmed/31671073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI126896
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items